Health
Roche Not Alarmed by Obesity Drug’s Side Effects, R&D Head Says
- CT-388 looks ‘as good as any other in this class:’ Clevers
- Roche opens new research, development center in Basel
This article is for subscribers only.
Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday.
“We’re not alarmed at all,” Hans Clevers, head of pharma research and early development at Roche, said at the opening of a research center in Basel. “This looks as good as any other in this class.”